Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
12.68
-1.07 (-7.78%)
At close: Jan 17, 2025, 4:00 PM
13.17
+0.49 (3.86%)
After-hours: Jan 17, 2025, 6:23 PM EST
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ARQT stock have an average target of 17, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 34.07% from the current stock price of 12.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ARQT stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 0 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +49.84% | Jan 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +57.73% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +49.84% | Dec 30, 2024 |
| Needham | Needham | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +57.73% | Dec 17, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +41.96% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
184.20M
from 59.61M
Increased by 209.03%
Revenue Next Year
274.45M
from 184.20M
Increased by 49.00%
EPS This Year
-1.38
from -3.78
EPS Next Year
-1.00
from -1.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 192.9M | 313.6M | 498.8M | |||
| Avg | 184.2M | 274.5M | 418.2M | |||
| Low | 174.4M | 217.5M | 274.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 223.6% | 70.3% | 81.7% | |||
| Avg | 209.0% | 49.0% | 52.4% | |||
| Low | 192.7% | 18.1% | -0.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.30 | -0.82 | 0.42 | |||
| Avg | -1.38 | -1.00 | -0.04 | |||
| Low | -1.40 | -1.15 | -0.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.